A Comparative Analysis Of The Pharmaceutical Markets Of Brazil And Mexico
BMI View: Brazil and Mexico have been essential for the commercial performance of multinational pharmaceutical companies in Latin America. Brazil's traditional commitment to healthcare has made the country very lucrative for many multinational pharmaceutical companies. However, the often intimate relationship between multinationals and Brazilian authorities, and deeper integration with local drugmakers, may become their undoing in long-term. Mexico has demonstrated many promising aspects for the development of multinationals in Latin America, such as its inclination to free trade and encouraging macroeconomic growth prospects. However, in short term, the relatively less investment in healthcare and low drug spending capacity will hinder multinationals to fully materialise their commercial benefits in the country.
Pharmaceutical Revenue Generating Opportunities
The pharmaceutical market of Latin America has become increasingly important yet challenging for multinational drugmakers. The Brazilian drug market is an integral component of the strategic outlook for many major pharmaceutical companies. Pharmaceutical public-private partnerships (PPPs) have been a prominent driving force for multinational companies' revenue growth in Brazil. In 2014, we believe that multinational drugmakers will continue to enjoy secured revenue streams under the deal terms, given the significant influence of the Brazilian government in local drug market; however, multinationals will eventually lose their advanced technologies and market shares to local drugmakers.
|Brazilian Market Performance Significantly Impacts Regional Growth|
|Sanofi Revenue In Latin America (EURmn)|